You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Long-acting PTH for hypoparathyroidism

    SBC: EXTEND BIOSCIENCES INC            Topic: NIDDK

    Project Summary Hypoparathyroidism is a rare disease that results from a deficiency or inability to make sufficient amounts of parathyroid hormonePTHUntreated or inadequately treated hypoparathyroidism leads to clinically significant mineral related metabolic issues including hypocalcemiawhich leads to heart arrhythmiasspasms of the vocal cordsand seizuresCurrent management of the disease for the ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Development of PAR2 Pepducins as a Novel NASH Treatment

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: 300

    Non alcoholic steatohepatitisNASHis characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosiscirrhosis and high mortality ratesNASH is frequently associated with other common metabolic abnormalitiessuch as insulin resistance and visceral obesityLiver transplantation is currently the only effective therapeutic approach for seve ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD

    SBC: THERAPYX, INC.            Topic: NIAID

    Abstract TGF NanoCapis an oral combination of nanoparticulate transforming growth factor betaTGFand alltrans retinoic acidATRAin pre clinical development for treatment of inflammatory bowel diseaseIBDPhase I studies provided proof of principle for efficacy in a murine modelPhase II work optimized therapeutic protocolconfirmed efficacy in a second modelestablished scale up manufacturing methodscomp ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid Molecular Detection of Tuberculosis without PCR amplification

    SBC: SCANOGEN INC.            Topic: NIAID

    Project Summary TuberculosisTBis a major global burden that killsmillion people every yearTB mostly affects developing countriesbut the rise of multi drug and extensively drug resistant strains is a global threatIn order to control and eradicate this diseaseit is imperative to have adequate tools to detect active TB in limited resource settings and point of carePOCsettingswhich is where most TB pa ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Commercializing Praedicare Dx TM platform for guiding cancer treatments

    SBC: Eutropics Pharmaceuticals, Inc.            Topic: 102

    Abstract The Eutropics PraediCare Dxis an emerging clinical diagnostic assay that will be used to predict patient response to specific chemotherapiesUnlike existing assaysPraediCare Dxpredicts response to specific chemotherapies by direct evaluation of cancer cells potential to enter into an apoptotic state following exposure to therapyPraediCare Dxhas the potential to provide actionable data for ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Marketing Strategic Plan and Distribution Logistics for Sanaria PfSPZ Vaccine against Malaria.

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT The development of Sanaria s Plasmodium falciparumPfsporozoiteSPZbased vaccines is receiving overwhelming global support after the publication inin Science of clinical data showingprotection against controlled human malaria infectionCHMIfollowing intravenous administration ofdoses of SanariaPfSPZ Vaccinecomposed of purifiedasepticradiation attenuatedcryopreserved PfSPZ meeting all regulat ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture

    SBC: SANARIA INC.            Topic: NIAID

    Abstract An ideal tool for eliminating Plasmodium falciparumPfthe causative agent ofof all malaria deathswould be a highly effective vaccine that prevents blood stage infection and thereby prevents both disease and transmissionSanaria has developed two effective vaccines that are phaseclinical trialsPf sporozoiteSPZvaccine that prevents Pf blood stage infection in andgtof recipients and PfSPZ Chal ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings

    SBC: ALDATU BIOSCIENCES INC            Topic: R

    TheWHO guidelines recommend anti retroviral therapyARTfor all HIV infected peopleand massive efforts to expand ART access will result in andgtM adults and andgtM children on ART byat a cost of almost US$BConsequentlythe number of patients prescribed alternativeprotease inhibitorPIbased ART following failure of first line regimens will also increaseStudies of patients on PI based ART in resource li ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Eliminating Ventricular Tachycardia:First in Human Clinical Trial using the Durablate Catheter

    SBC: Thermedical Inc.            Topic: NHLBI

    Ischemic ventricular tachycardiaVTcauses more than half of thesudden cardiac deathsSCDthat occur annually in the United StatesImplantable cardioverter defibrillatorsICDsare the standard of carebut they are expensivethe total cost of an ICD implant exceeds $and not curativePatients who receive ICDs are subject to periodic shocks to halt episodes of VTand those shocks can be traumaticRF ablation rep ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease

    SBC: BIOSENSICS LLC            Topic: 106

    ABSTRACT The principal means of measuring motor impairment in Huntington diseaseHDis the Unified Huntington s Disease Rating ScaleUHDRStotal motor scorewhich is subjective and categoricalWearable sensors could enable objectivesensitivecontinuous assessment of motor impairments in individuals with a variety of neurological movement disordersThis is important because large amounts of objective data ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government